会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • COMPOSITIONS AND METHODS FOR DETECTING GROUP A STREPTOCOCCUS
    • EP4407046A3
    • 2024-10-16
    • EP24172440.0
    • 2020-03-20
    • Gen-Probe Incorporated
    • PANUGANTI, Sree DivyaSHAH, Ankur
    • C12Q1/689
    • C12Q1/689
    • There is described a composition or kit comprising at least first and second amplification oligomers, wherein:(a) the first amplification oligomer and second amplification oligomer are configured to amplify a Group A Streptococcus amplicon; (b) the first amplification oligomer: (i) comprises a first sequence which is SEQ ID NO: 4; (ii) comprises a sequence with 0, 1, or 2 mismatches to a first sequence which is SEQ ID NO: 4; (iii) competes for hybridization to a Group A Streptococcus (GAS) nucleic acid under stringent conditions with an amplification oligomer whose sequence consists of a first sequence which is SEQ ID NO: 4; or (iv) comprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of a first sequence which is SEQ ID NO: 4; and (c) the second amplification oligomer: (i) comprises a second sequence which is SEQ ID NO: 6; (ii) comprises a sequence with 0, 1, or 2 mismatches to a second sequence which is SEQ ID NO: 6; (iii) competes for hybridization to a Group A Streptococcus (GAS) nucleic acid under stringent conditions with an amplification oligomer whose sequence consists of a second sequence which is SEQ ID NO: 6; or (iv) comprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of a second sequence which is SEQ ID NO: 6.
    • 2. 发明公开
    • COMPOSITIONS AND METHODS FOR DETECTING SHIGELLA AND AT LEAST ONE OF SALMONELLA, C. JEJUNI, C. COLI, AND STEC
    • EP4382622A3
    • 2024-08-21
    • EP24165401.1
    • 2022-07-26
    • Gen-Probe Incorporated
    • PANUGANTI, Sree Divya
    • C12Q1/689
    • C12Q1/689C12Q1/686Y02A50/30C12Q2600/1620130101
    • There is described a set of oligonucleotides for determining the presence or absence of at least two enteric pathogens, said set of oligonucleotides comprising (a) and at least one of (b)-(e): (a) a Shigella-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:15 and SEQ ID NO:17; (ii) SEQ ID NO:34 and SEQ ID NO:22; or (iii) SEQ ID NO:32 and SEQ ID NO:33; (b) a Salmonella-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:12 and SEQ ID NO:14; (ii) SEQ ID NO:21 and SEQ ID NO:47; (iii) SEQ ID NO:38 and SEQ ID NO:36; (iv) SEQ ID NO:35 and SEQ ID NO:40; (v) SEQ ID NO:12 and SEQ ID NO:28; (vi) SEQ ID NO:42 and SEQ ID NO:31; or (vii) SEQ ID NO:41 and SEQ ID NO:27; (c)a C. jejuni-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: SEQ ID NO:11 and SEQ ID NO: 19; (d) a C. coli-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:8 and SEQ ID NO:10; and (e) a Shigatoxigenic E. coli (STEC)-specific amplification oligomer set comprising first and second oligomers respectively comprising target-hybridizing sequences consisting of the nucleotide sequences of: (i) SEQ ID NO:20 and SEQ ID NO:3; (ii) SEQ ID NO:49 and SEQ ID NO:3; or (iii) SEQ ID NO:4 and SEQ ID NO:7.
    • 3. 发明公开
    • COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS AND AT LEAST ONE OF METAPNEUMOVIRUS AND RHINOVIRUS NUCLEIC ACIDS
    • EP4382619A3
    • 2024-08-21
    • EP24168848.0
    • 2018-03-23
    • Gen-Probe Incorporated
    • MAJLESSI, Mehrdad R.SHAH, AnkurDOUGLASS, PamelaKOLK, Daniel P.HILLIUS, Amber
    • C12Q1/70C12Q1/6888
    • C12Q1/701C12Q2600/1620130101C12Q1/6888
    • There is disclosed a composition comprising a combination of amplification oligomers configured for amplification of an Adenovirus target nucleic acid and at least one additional target nucleic acid selected from the group consisting of a Metapneumovirus target nucleic acid and a Rhinovirus target nucleic acid, wherein: (A) for the Adenovirus target nucleic acid, a first Adenovirus amplification oligomer and a second Adenovirus amplification oligomer are configured to amplify an Adenovirus amplicon of at least about 50 nucleotides in length comprising at least one Adenovirus position located in the range of nucleotide positions 52 to 74 of SEQ ID NO:47, nucleotide positions 76 to 99 of SEQ ID NO:47, nucleotide positions 40 to 56 of SEQ ID NO:47, nucleotide positions 65 to 87 of SEQ ID NO:47, nucleotide positions 1 to 18 of SEQ ID NO:47, nucleotide positions 7 to 23 of SEQ ID NO:47, nucleotide positions 28 to 45 of SEQ ID NO:47, nucleotide positions 27 to 45 of SEQ ID NO:47, nucleotide positions 26 to 45 of SEQ ID NO:47, nucleotide positions 139 to 155 of SEQ ID NO:47, nucleotide positions 103 to 123 of SEQ ID NO:47, nucleotide positions 159 to 175 of SEQ ID NO:47, nucleotide positions 83 to 99 of SEQ ID NO:47, and/or nucleotide positions 83 to 98 of SEQ ID NO:47; and (B) for the at least one additional target nucleic acid, (1) a first Metapneumovirus amplification oligomer and a second Metapneumovirus amplification oligomer are configured to amplify a Metapneumovirus amplicon of at least about 50 nucleotides in length comprising at least one Metapneumovirus position located in the range of nucleotide positions 966 to 1147 of SEQ ID NO:150, nucleotides 844 to 1027 of SEQ ID NO:159, nucleotide positions 1000 to 1040 of SEQ ID NO:150, nucleotide positions 880 to 915 of SEQ ID NO:159, nucleotide positions 1027 to 1080 of SEQ ID NO:150, nucleotide positions 913 to 958 of SEQ ID NO:159, nucleotide positions 1073 to 1115 of SEQ ID NO:150, and/or nucleotide positions 953 to 995 of SEQ ID NO:159; and/or (2) a first Rhinovirus amplification oligomer and a second Rhinovirus amplification oligomer are configured to amplify a Rhinovirus amplicon of at least 50 nucleotides in length comprising at least one Rhinovirus position located in the range of nucleotide positions 230 to 556 of SEQ ID NO:120, nucleotide positions 199 to 525 of SEQ ID NO:101, nucleotide positions 80 to 410 of SEQ ID NO:76, nucleotide positions 263 to 303 of SEQ ID NO:120, nucleotide positions 231 to 264 of SEQ ID NO:101, nucleotide positions 106 to 156 of SEQ ID NO:76, nucleotide positions 312 to 346 of SEQ ID NO:120, nucleotide positions 279 to 314 of SEQ ID NO:101, nucleotide positions 455 to 506 of SEQ ID NO:76, nucleotide positions 480 to 533 of SEQ ID NO:120, nucleotide positions 455 to 506 of SEQ ID NO:101, and/or nucleotide positions 338 to 397 of SEQ ID NO:76.
    • 4. 发明公开
    • AUTOMATED SYSTEMS AND METHODS FOR LOADING SOLID REAGENT PELLETS INTO WELLS OF A CARTRIDGE
    • EP4414712A2
    • 2024-08-14
    • EP24184641.9
    • 2022-07-28
    • Gen-Probe Incorporated
    • SILBERT, Rolf
    • G01N35/10
    • G01N35/0099G01N35/1002G01N35/109G01N35/00584G01N35/1074G01N2035/0005920130101G01N2035/0057420130101
    • There is described a method for automatically supplying a dried reagent pellet (102) to each well of a cartridge comprising a plurality of wells, wherein the method comprises: (A) automatically positioning a pellet transfer head above a pellet supply reservoir containing a supply of dried reagent pellets, wherein the pellet transfer head comprises (i) a plurality of vacuum nozzles, wherein each vacuum nozzle comprises a downwardly-facing vacuum port in selective communication with a vacuum source and wherein the number and arrangement of the vacuum nozzles corresponds to the number and arrangement of wells of the cartridge and (ii) one or more downwardly-facing pressure ports in selective communication with a pressure source; (B) after step (A), automatically lowering the pellet transfer head to a pellet pickup position with respect to the pellet supply reservoir; (C) with the pellet transfer head in the pellet pickup position, activating the pressure source to supply gas flow at the one or more pressure ports of the pellet transfer head to fluidize the supply of pellets within the pellet supply reservoir and activating the vacuum source to create a vacuum at each vacuum port to draw a pellet from the pellet supply reservoir to each vacuum port; (D) after step (C), automatically raising the pellet transfer head from the pellet pickup position with respect to the pellet supply reservoir; (E) after step (D), automatically positioning the pellet transfer head within a field of view of a vision sensor camera; (F) after step (E), activating the vision sensor camera and a vision sensor system to detect whether a dried reagent pellet is disposed at each of the vacuum nozzles; (G) after step (F), automatically positioning the pellet transfer head above the cartridge so that each vacuum nozzle is aligned with a corresponding well of the cartridge; (H) after step (G), automatically lowering the pellet transfer head to a pellet dispensing position with respect to the cartridge; and (I) after step (H), deactivating the vacuum source to terminate the vacuum at each vacuum port to release the pellet from each vacuum nozzle into the corresponding well of the cartridge.